---
title: HB 1329. Controlled substances; Schedule I; provide certain provisions
collection: bills
id: 2025-2026/hb1329
cite_as: HB 1329, 2025-2026 Regular Session (Ga.)
canonical_url: https://georgiacommons.org/bills/2025-2026/hb1329
md_url: https://georgiacommons.org/bills/2025-2026/hb1329.md
text_url: https://georgiacommons.org/bills/2025-2026/hb1329/text
source_url: https://www.legis.ga.gov/legislation/73260
date: 2026-05-05
status: passed
corpus_version: bills-2026-09-13
license: Public record of the Georgia General Assembly, via LegiScan; see about.md
publisher: Georgia Commons, an independent project of Georgia Civic Data. Not the State of Georgia. Not legal advice.
up: https://georgiacommons.org/bills/2025-2026.md
previous: https://georgiacommons.org/bills/2025-2026/hb1328.md
next: https://georgiacommons.org/bills/2025-2026/hb1330.md
index: https://georgiacommons.org/bills/index.md
omitted: votes and history
omitted_chars: 949
omitted_url: https://georgiacommons.org/bills/2025-2026/hb1329.md?full=1
bill_number: HB 1329
session: 2025-2026 Regular Session
session_slug: 2025-2026
chamber: House
bill_type: bill
status_date: 2026-05-05
last_action: Effective Date 2026-05-05
sponsors:
- Ron Stephens
- Mark Newton
- Ben Watson
text_version: Enrolled
has_text: true
legiscan_url: https://legiscan.com/GA/bill/HB1329/2025
upstream_id: 2118564
summaries_model: claude-sonnet-5
topic_tags:
- controlled substances
- drug scheduling
- pharmacy regulation
- epinephrine access
- prescription drugs
---
# HB 1329. Controlled substances; Schedule I; provide certain provisions
## Text
House Bill 1329 (AS PASSED HOUSE AND SENATE)
By: Representatives Stephens of the 164th and Newton of the 127th
A BILL TO BE ENTITLED
AN ACT
To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
controlled substances, so as to provide for certain provisions relating to Schedule I controlled
substances; to provide for certain provisions relating to the definition of dangerous drugs; to
provide for related matters; to provide for an effective date; to repeal conflicting laws; and
for other purposes.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION 1.
Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
substances, is amended in Code Section 16-13-25, relating to Schedule I controlled
substances, by revising subparagraph (E) of paragraph (16) as follows:
"(E) By substitution at the 5-position or 6-position with a nitro, alkyl, halide, cyano,
or acetyl group or primary amine;"
SECTION 2.
Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by
adding new paragraphs to subsection (b) to read as follows:
"(1.5) Aceclidine;"
"(12.7) Acoltremon;"
"(17.2) Aficamten;"
"(68.45) Atrasentan;"
"(69.21) Avutometinib;"
"(91.71) Berahyaluronidase alfa-pmph;"
"(106.4) Brensocatib;"
"(196.3) Clesrovimab-cfor;"
"(240.97) Datopotamab deruxtecan-dlnk;"
"(243.4) Defactinib;"
"(244.7) Delgocitinib;"
"(248.5) Depemokimab-ulaa;"
"(316.6) Donidalorsen;"
"(317.15) Dordaviprone;"
"(318.7) Doxecitine;"
"(320.5) Doxribtimine;"
"(331.0513) Elamipretide;"
"(331.0555) Elinzanetant;"
"(379.8) Etripamil;"
"(386.95) Fitusiran;"
"(411.9) Garadacimab-gxii;"
"(414.4) Gepotidacin;"
"(466.7) Imlunestrant;"
"(513.75) Lerodalcibep-liga;"
"(523.5) Linvoseltamab-gcpt;"
"(619.15) Mirdametinib;"
"(640.105) Nerandomilast;"
"(644.605) Nipocalimab-aahu;"
"(663.65) Onasemnogene abeparvovec-brve;"
"(681.65) Paltusotine;"
"(698.5) Penpulimab-kcqx;"
"(742.7) Plozasiran;"
"(768.6) Prademagene zamikeracel;"
"(832.975) Remibrutinib;"
"(836.6) Revakinagene taroretcel-lwey;"
"(842.3) Rilzabrutinib;"
"(852.055) Sebetralstat;"
"(855.1) Sepiapterin;"
"(855.735) Sevabertinib;"
"(855.83) Sibeprenlimab-szsi;"
"(927.8) Sunvozertinib;"
"(929.7) Suzetrigine;"
"(930.978) Taletrectinib;"
"(931.565) Telisotuzumab vedotin-tllv;"
"(974.65) Treosulfan;"
"(1030.9) Vimseltinib;"
"(1042.2) Ziftomenib;"
"(1042.85) Zoliflodacin;"
"(1042.91) Zongertinib;"
"(1042.93) Zopapogene imadenovec-drba;"
SECTION 3.
Said chapter is further amended in subsection (b) of said Code section by repealing and
reserving paragraph (324) and by revising paragraphs (60.3), (160.5), and (217.2) as follows:
"(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;"
"(160.5) Chikungunya vaccine, Live;"
"(217.2) COVID-19 Vaccine, mRNA;"
SECTION 4.
Said chapter is further amended in subsection (c) of said Code section by revising paragraph
(9.33) as follows:
"(9.33) Epinephrine —:
(A) When when used in a device that delivers a metered spray of 0.125 mg. of
epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma
and is a product in finished dosage formulation in its original container that has been
approved by and labeled in compliance with the U.S. Food and Drug Administration
(FDA); and
(B) When distributed by a pharmacist as provided by the State Board of Pharmacy, in a
device that delivers a spray of 2 mg. of epinephrine or less to provide emergency
treatment of allergic reactions, including anaphylaxis, and is a product in finished dosage
formulation in its original container that has been approved by and labeled in compliance
with the U.S. Food and Drug Administration (FDA);"
SECTION 5.
This Act shall become effective upon its approval by the Governor or upon its becoming law
without such approval.
SECTION 6.
All laws and parts of laws in conflict with this Act are repealed.
## Summaries written by Georgia Commons
The following was written by claude-sonnet-5 from the text above and is not part of the bill. Quote the text, not the summary.
House Bill 1329 updates Georgia's controlled substances law by adding dozens of new medications to the state's list of dangerous drugs and adjusting a Schedule I chemical definition, largely to keep pace with newly approved pharmaceuticals.
### Plain-language summary
Georgia law separately lists which chemicals count as Schedule I controlled substances and which medications count as 'dangerous drugs' that require a prescription. This bill updates both lists. It expands the chemical definition used to identify certain Schedule I synthetic cannabinoid-type substances by adding alkyl, halide, cyano, or acetyl groups to the list of substitutions that trigger control, alongside the existing nitro group language.
The bill also adds roughly 50 newly named drugs, mostly recently approved prescription medications with generic names like aceclidine, brensocatib, and suzetrigine, to the dangerous drugs list in O.C.G.A. § 16-13-71. It removes outdated entries for specific brand formulations of an antihemophilic factor, a chikungunya vaccine, and a COVID-19 vaccine, and it expands an exception for epinephrine devices to cover pharmacist-distributed higher-dose epinephrine sprays used for severe allergic reactions. The law would take effect as soon as the Governor signs it.
### What it does
- Broadens the chemical description used to classify certain Schedule I controlled substances by adding alkyl, halide, cyano, or acetyl substitution groups to the existing nitro-group definition.
- Adds about 50 newly named prescription drugs, identified by generic name, to Georgia's list of regulated dangerous drugs under O.C.G.A. § 16-13-71.
- Repeals outdated paragraph listings for a specific antihemophilic factor formulation, a live chikungunya vaccine, and an mRNA COVID-19 vaccine from the dangerous drugs list.
- Expands the epinephrine exemption so pharmacists can distribute higher-dose epinephrine sprays (up to 2 mg) for emergency allergic reaction treatment without the drug being treated as a controlled dangerous drug requiring separate handling.
- Sets the effective date as the day the Governor signs the bill or it otherwise becomes law.
### Who it affects
Pharmacists, physicians, and pharmacies that dispense the newly listed medications; drug manufacturers whose products are added or removed from the dangerous drugs list; patients relying on epinephrine devices for allergic reactions; and law enforcement or prosecutors who apply Georgia's controlled substances definitions.
### Why it matters
By updating which chemicals and medications count as regulated substances, the bill keeps Georgia's drug schedules current with newly approved treatments and vaccine formulations. Expanding the epinephrine exception could make it easier for pharmacists to distribute higher-dose emergency allergy treatments under existing rules.
### Key provisions
- Section 1 revises O.C.G.A. § 16-13-25(16)(E) to add alkyl, halide, cyano, and acetyl substitution groups to the Schedule I chemical definition, alongside the existing nitro group and primary amine language.
- Section 2 adds roughly 50 new paragraphs to O.C.G.A. § 16-13-71(b) naming specific drugs, from aceclidine to zopapogene imadenovec-drba, as dangerous drugs.
- Section 3 repeals and reserves paragraph (324) and revises paragraphs (60.3), (160.5), and (217.2) to remove specific antihemophilic factor, chikungunya vaccine, and COVID-19 vaccine listings.
- Section 4 revises O.C.G.A. § 16-13-71(c)(9.33) to add a second epinephrine exemption for pharmacist-distributed sprays delivering up to 2 mg for emergency allergic reaction treatment.
- Section 5 makes the Act effective upon the Governor's approval or upon becoming law without approval.
- Section 6 repeals all conflicting laws.
## Status
- Status: Passed (2026-05-05)
- Last action: Effective Date 2026-05-05 (2026-05-05)
- Sponsors: Ron Stephens, Mark Newton, Ben Watson
- Official page: https://www.legis.ga.gov/legislation/73260
> The history, votes, and amendments (949 characters) are at https://georgiacommons.org/bills/2025-2026/hb1329.md?full=1